应用风险评分识别社区发病肺炎的老年人最有可能从经验性假单胞菌治疗中获益

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pub Date : 2017-02-01 DOI:10.1002/phar.1891

C. Frei, Sylvie B. Rehani, Grace C. Lee, N. Boyd, Erene M. Attia, A. Pechal, Rachel S. Britt, E. Mortensen

{"title":"应用风险评分识别社区发病肺炎的老年人最有可能从经验性假单胞菌治疗中获益","authors":"C. Frei, Sylvie B. Rehani, Grace C. Lee, N. Boyd, Erene M. Attia, A. Pechal, Rachel S. Britt, E. Mortensen","doi":"10.1002/phar.1891","DOIUrl":null,"url":null,"abstract":"To assess the impact of empiric Pseudomonas pharmacotherapy on 30‐day mortality in hospitalized patients with community‐onset pneumonia stratified according to their risk (low, medium, or high) of drug‐resistant pathogens.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Application of a Risk Score to Identify Older Adults with Community‐Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy\",\"authors\":\"C. Frei, Sylvie B. Rehani, Grace C. Lee, N. Boyd, Erene M. Attia, A. Pechal, Rachel S. Britt, E. Mortensen\",\"doi\":\"10.1002/phar.1891\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To assess the impact of empiric Pseudomonas pharmacotherapy on 30‐day mortality in hospitalized patients with community‐onset pneumonia stratified according to their risk (low, medium, or high) of drug‐resistant pathogens.\",\"PeriodicalId\":19812,\"journal\":{\"name\":\"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/phar.1891\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/phar.1891","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

评估经验性假单胞菌药物治疗对社区发病肺炎住院患者30天死亡率的影响，根据耐药病原体的风险(低、中、高)进行分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Application of a Risk Score to Identify Older Adults with Community‐Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy

To assess the impact of empiric Pseudomonas pharmacotherapy on 30‐day mortality in hospitalized patients with community‐onset pneumonia stratified according to their risk (low, medium, or high) of drug‐resistant pathogens.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

自引率

0.00%

发文量